tiprankstipranks
Trending News
More News >

Telix Pharmaceuticals Expands Market Presence with New Securities Quotation

Story Highlights
Telix Pharmaceuticals Expands Market Presence with New Securities Quotation

Confident Investing Starts Here:

The latest update is out from Telix Pharmaceuticals ( (AU:TLX) ).

Telix Pharmaceuticals Limited has announced the quotation of 139,383 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective May 12, 2025. This move reflects the company’s ongoing efforts to enhance its market presence and provide value to its stakeholders by expanding its capital base.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.30 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

More about Telix Pharmaceuticals

Telix Pharmaceuticals Limited operates in the biotechnology industry, focusing on the development and commercialization of diagnostic and therapeutic products using molecularly targeted radiation. The company primarily serves the healthcare sector, offering innovative solutions for cancer treatment and diagnosis.

Average Trading Volume: 1,968,807

Technical Sentiment Signal: Buy

Current Market Cap: A$8.64B

For an in-depth examination of TLX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App